Variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have been associated with increased risk for sporadic, late-onset Alzheimer's disease. Here we show that germline knockout of Trem2 or the TREM2
1
. In addition, carriers of TREM2 variants have a faster rate of cognitive decline, suggesting that TREM2 also influences disease progression 2 . Previous studies by our group and others have characterized the effects of TREM2 deficiency on amyloid-β plaques, which are thought to be an initiator of AD 3 , and found that the loss or reduction of TREM2 function decreased microgliosis surrounding plaques in multiple mouse models and in humans expressing the AD risk allele, TREM2 R47H (refs. [4] [5] [6] [7] [8] [9] [10] [11] [12] ). This corresponds with increased neuritic dystrophy around plaques 7, 8, [10] [11] [12] . Together, TREM2 genetic and functional data insinuate that microglia are critical to mitigation of damage inflicted by nearby amyloid-β plaques; yet, how these protective microglial actions and the TREM2 variants that interrupt them contribute to AD risk and progression remains ambiguous.
Swollen, dystrophic neural processes that contain aggregated, phosphorylated tau (p-tau) surrounding amyloid-β deposits are a key feature of neuritic plaques (NPs), a hallmark pathology of AD. The other pathological protein aggregate that defines AD, neurofibrillary tangles (NFTs), is also composed of p-tau. NFTs are mostly found in the medial temporal lobe of cognitively normal individuals with and without preclinical AD. Progression of tau pathology into the limbic and neocortex with antecedent amyloid-β pathology coincides with cognitive impairment 13 . A recent study demonstrated that the presence of amyloid plaques facilitated local tau seeding in dystrophic neurites that later spurred the spread and formation of p-tau in NPs and NFTs in mice 14 . This strengthens the hypothesis that amyloid-β plaque accumulation damages adjacent neural processes, creating a favorable environment for early NP tau aggregation that can facilitate greater p-tau expansion in NPs and NFTs, and hence AD progression. Previous studies support the idea that microglia limit peri-plaque neuritic dystrophy; 7, 8, [10] [11] [12] 15 therefore, we reasoned that loss of plaque-associated microglia in mice with reduced or null TREM2 function would further exacerbate seeded NP tau formation, aggregation, and spreading.
To investigate the effects of TREM2 deficiency and the TREM2 R47H AD risk variant on NP tau pathology, we used a newly developed model in which endogenous mouse tau is induced to have AD-like tau features by seeding the brain with sarkosylinsoluble tau aggregates isolated from the frontal cortex of human AD brain tissue (AD-tau), prepared as described previously 14, 16 .
APPPS1-21 Trem2
+/+ (T2WT) or Trem2 −/− (T2KO) mice 4 and APPPS1-21 mice expressing the human TREM2 common variant (T2CV) or R47H AD risk variant (T2R47H) on a mouse T2KO background 8 were unilaterally injected at 5.5 months of age in the dentate gyrus and overlying cortex (1 µg per site) and analyzed 3 months post injection (p.i.). APPPS1-21 mice have substantial cortical and early hippocampal amyloid-β pathology by 5.5 months, even in the absence of TREM2 (ref. 4 ), yet negligible NP tau aggregation that can be identified by immunostaining. However, injection of AD-tau in mice with amyloid-β plaques was reported to preferentially induce NP tau aggregates as opposed to NFTs by 3 months p.i. (ref. 14 
)
. We observed widespread seeded NP tau aggregation throughout the ipsilateral cortex of APPPS1-21 mice as well as spread to the contralateral cortex using this experimental paradigm (characterization of unseeded and seeded APPPS1-21 mice in Supplementary Fig. 1 ) that was remarkably elevated in T2KO and T2R47H mice compared to T2WT and T2CV mice, respectively (Fig. 1a-f) . Notably, human tau was not detected in AD-tau treated mice ( Supplementary Fig.  2 ), which indicates that aggregates were composed of seeded mouse tau, as described previously 16 . NP tau aggregates were not observed in the absence of amyloid-β plaques ( Supplementary Fig. 3 ), also consistent with previous findings 14 . We did not detect a difference in cortical, fibrillar amyloid-β plaque burden between T2WT and T2KO mice or between T2CV and T2R47H mice ( Supplementary  Fig. 4 ). Minimal NFTs distant from plaques were observed using this experimental strategy ( Supplementary Fig. 5 ) and model. Nominal hippocampal NP tau seeding was detected ( Supplementary Fig. 1 ), probably due to the comparatively lower hippocampal versus cortical amyloid-β plaque burden in this model ( Supplementary Fig. 4) , and was therefore not assessed. To confirm that cortical NP tau . Scale bars, 250 µm. c-f, Quantification of AT8 staining in the ipsilateral and contralateral cortices of T2WT and T2KO mice (t (11) , ipsilateral **P = 0.0039, contralateral ***P = 0.0005) (c,d) or T2CV and T2R47H mice (t (12) , ipsilateral *P = 0.0484, contralateral P = 0.1466) (e,f). g,h, Confocal images of cortical AT8 + NP tau (red) around X34 + plaques (blue). Scale bars, 50 µm. i-l, Quantification of the percent of AT8 + voxels within 15 µm of plaques in T2WT and T2KO mice (t (11) , ipsilateral **P = 0.0066, contralateral ***P < 0.0001) (i,j) or T2CV and T2R47H mice (t (12) , ipsilateral **P = 0.0064, contralateral *P = 0.0311) (k,l). Significance determined by unpaired, twosided student's t-test for T2WT (n = 6) and T2KO (n = 7) or T2CV (n = 7) and T2R47H (n = 7). Individual data points are plotted for each group ± s.e.m.
aggregation was increased independent of the number of amyloid-β plaques, we performed confocal analysis and quantified the amount of NP tau surrounding individual X34-positive (X34 + ) amyloid-β plaques ( Fig. 1g-l) . This corroborated the idea that seeded NP tau pathology was increased significantly with loss of TREM2 function and in the setting of the TREM R47H variant, regardless of plaque size ( Supplementary Fig. 6a,b) . Notably, a portion of the NP tau surrounding plaques also co-localized with X34, indicative of a more advanced, fibrillar p-tau aggregate ( Supplementary Fig.  7a,b) . All seeded mice contained some fibrillar NP tau, but these aggregates were notably pronounced in T2KO and R47H mice ( Supplementary Fig. 7c,d) . Altogether, these data support the idea that loss of TREM2 function increases the burden of seeded periplaque p-tau deposits.
We next investigated how reduced TREM2 function could facilitate NP tau seeding. As expected [4] [5] [6] [7] [8] 10, 11 , we observed reduced plaque-associated microgliosis in T2KO and T2R47H mice compared to T2WT and T2CV mice, respectively (Fig. 2a-f) . Several previous publications have reported increased neuritic dystrophy around plaques in TREM2-deficient models or in the presence of the R47H variant 7, 8, 11, 12 . We labeled dystrophic neurites by immunostaining for BACE1, which accumulates in dystrophic neuronal processes 17 , and observed a strong correlation between the amount of BACE1-labeled processes and AT8 staining (Fig. 2g,h ). Although some co-localization was detected, we unexpectedly found that many AT8
+ neurites did not co-localize with BACE1, which suggests that dystrophic neurites are a heterogenous population of structures, perhaps with different proclivity for seeding of aggregated p-tau 15, 17 . Despite their poor overall co-localization, the strong positive correlation between BACE1 and AT8 suggests that overall amyloid-β plaque-induced neuronal toxicity contributes to a favorable environment for the induction of pathological tau seeding. Although plaques are composed of different amyloid-β species, amyloid-β 42 in particular is neurotoxic and can affect microtubule stability and tau phosphorylation 3 . One recent study described an inverse relationship between encapsulation of plaques by microglial processes and amyloid-β 42 'hot-spots' on plaques, which is also consistent with increased dystrophic neurites 15 . Therefore, we tested whether TREM2 deficiency affected amyloid-β 42 immunoreactivity within amyloid plaques. Confocal analysis of plaques co-stained with X34 and a C-terminal, amyloid-β 42 -specific antibody revealed significant increases of amyloid-β 42 in and around X34 + plaques in the ipsilateral cortex of T2KO and R47H mice ( Fig. 2i-n) , regardless of plaque size ( Supplementary   Fig. 6c,d ). Figure 2o -p illustrates that NP tau seeding is preferentially increased in T2KO and T2R47H mice as a function of the number of plaque-associated microglia and the percentage of plaques comprised of increased amyloid-β 42 .
Finally, we assessed whether human AD cases from carriers of AD-associated TREM2 variants exhibited similar elevations in NP tau. We examined prefrontal cortex tissue from carriers of late-onset AD TREM2 R47H and TREM2 R62H variants, and their case-matched controls. Consistent with our mouse data and a previous study 7 , we detected significantly more p-tau around plaques in carriers of the TREM2 AD risk variants (Fig. 3a,b) . The increase in NP tau staining in carriers of AD-associated TREM2 variants was independent of APOEε4 genotype, consistent with a recent report that reduced microgliosis in carriers of TREM2 variants was independent of APOEε4 genotype ( Supplementary  Fig. 8 ) 12 . The increase in NP tau staining was also not attributable to overall changes in total insoluble tau or p-tau ( Fig. 3c-f) . Analysis of amyloid-β 42 staining around plaques did not reveal significant increases in amyloid-β 42 in carriers of TREM2 variants (Fig. 3g,h ). Given that we assessed end-stage AD cases (Supplementary Table 1 ), it is possible that the plaques have matured differently to those in our mouse model, which recapitulates the preclinical phase of the disease. There may also be additional factors contributing to amyloid-β 42 plaque composition and morphology in humans that are not fully recapitulated in APPPS1-21 mice. Future studies are needed to better delineate whether there is a relationship between amyloid-β 42 around plaques and NP tau deposition or loss of plaque-associated microglia in human carriers of TREM2 variants.
Previous studies have considered the effects of TREM2 function only in the context of either amyloid-β (refs. [4] [5] [6] [7] [8] [9] [10] [11] [12] ) or tau pathologies [18] [19] [20] . Here, we used a newly developed mouse model of both amyloid-β and tau aggregation 14 , and found that TREM2 deficiency and the TREM2 R47H variant increased susceptibility of tau seeding and spread in dystrophic neurons surrounding amyloid-β plaques, which also corresponded with more amyloid-β 42 accumulation and less microgliosis. A key question that remains unanswered in AD pathogenesis is how the accumulation of amyloid-β is linked to the progression of tau pathology in AD. Our data suggest that microglia and TREM2 lie at a critical intersection of amyloid-β and tau pathologies. TREM2-facilitated microglial association with plaques seems to limit damage to surrounding neuronal processes, possibly by containing toxic amyloid-β 42 species, and prevents early tau seeding events. Previous work showed that these NP tau aggregates + plaques (blue). c-f, Quantification of the number of microglial cells surrounding plaques in T2WT and T2KO (t (11) , ipsilateral **P = 0.0066, contralateral **P = 0.0088) (c,d) or T2CV and T2R47H mice (t (12) , ipsilateral **P = 0.0033, contralateral *P = 0.0409) (e,f). g, Confocal image of BACE1 (green) and AT8 (red) co-stained around X34 + plaques (blue). h, Pearson's correlation of BACE1 and AT8 staining in AD-tau seeded APPPS1-21 T2WT and T2KO mice (r = 0.9465, R 2 = 0.8959, P < 0.0001) and T2CV and T2R47H mice (r = 0.9393, R 2 = 0.8822, P < 0.0001). i,j, Confocal images of amyloid-β 42 (magenta) in and around X34 + plaques (blue). k-n, Quantification of the percentage of amyloid-β 42 + voxels within 15 µm of plaques in T2WT and T2KO (t (11) , ipsilateral **P = 0.0066, contralateral *P = 0.0121) (k,l) or T2CV and T2R47H mice (t (12) , ipsilateral **P = 0.0041, contralateral P = 0.0789) (m,n). All representative images from ipsilateral cortex. Scale bars, 50 µm. Significance determined by unpaired, two-sided student's t-test for T2WT (n = 6) and T2KO (n = 7) or T2CV (n = 7) and T2R47H (n = 7). Individual data points are plotted for each group ± s.e.m. o, Representative image of co-staining for X34 (blue), AT8 (red), amyloid-β 42 (magenta), and Iba1 (green) from a seeded APPPS1-21 T2KO mouse. Scale bar, 50 µm. p, Relationship between co-stained Iba1 + microglial cells (x axis), amyloid-β 42 (y axis), and seeded AT8 NP tau surrounding X34
+ plaques in the ipsilateral cortex. Each dot represents an individual mouse, the dot color indicates TREM2 genotype, and the dot size corresponds to percent AT8 + staining around plaques (reported in Fig. 1 ). Significant Pearson's correlations were observed between the number of microglia to the percent AT8 per plaque (r = −0.4531, R 2 = 0.2053, *P < 0.0176) and between percent amyloid-β 42 and AT8 (r = 0.8031, R 2 = 0.6405, ***P < 0.0001) surrounding plaques. A trend for a correlation was observed when comparing all groups for the number of microglia to percent amyloid-β 42 (r = −0.3463, R 2 = 0.1199, P = 0.0771). Significant comparisons and correlations between groups were initially observed in two separate experiments (co-staining for X34, AT8,and amyloid-β 42 or co-staining for X34 and Iba1). Subsequently, a quadruple stain was performed for all antigens (X34, AT8, amyloid-β 42 , and Iba1) within the same tissue sections; these data confirmed previous significant observations and are reported in Figs. 1 and 2 .
can lead to NFT formation 14 . Thus, our findings offer novel evidence of how TREM2 function in microglia limits amyloid-β plaque-mediated tau pathogenesis in AD. They also suggest that loss of plaque-associated microglia in carriers of TREM2 variants increases AD risk and disease progression by increasing susceptibility to the seeding and spreading of tau. + NP tau within 15 µm of X34 + plaques (t (15) , ***P = 0.0002). Significance determined by paired, two-sided t-test. c-f, Levels of soluble (t (24) , P = 0.6686) and insoluble total tau (t (24) , P = 0.9994) (c,d) and soluble (t (24) , P = 0.9594) and insoluble (t (24) , P = 0.8673) p-tau (e,f) in human AD cases (Supplementary Table 2 ). Significance determined by unpaired, two-sided student's t-test. Individual data points are plotted for each group ± s.e.m. g, Representative image from confocal analysis of amyloid-β 42 staining (magenta) surrounding X34 + plaques (blue) from human AD cases. h, Quantification of amyloid-β 42 within 15 µm of X34 + plaques (t (15) , P = 0.4107). Significance determined by paired, two-sided t-test. For immunostaining analysis, case-matched controls included TREM2 R47H n = 8, TREM2 R62H n = 7, TREM2 CV n = 14; one TREM2 CV was shared for two TREM2 variant cases. For biochemical analyses, TREM2
R47H n = 7, TREM2 R62H n = 7, TREM2 CV n = 11.
Methods
Animals. APPPS1-21 mice (a gift from M. Jucker) that co-express human amyloid precursor protein (APP) with a Swedish mutation (KM670/671NL) and human mutant presenilin 1 (PS1, L1669) under control of the Thy1 promoter 21 were crossed to either TREM2 +/+ (T2WT) or TREM2 −/− (T2KO) 22 mice to generate APPPS1-21/ T2WT (n = 6; 4 female, 2 male) or APPPS1-21/T2KO (n = 7; 4 female, 3 male) mice 4 . APPPS1-21 mice that were mouse T2KO were also crossed to mice that had been engineered using bacterial artificial chromosome (BAC) technology to express human TREM2 with either the common variant (T2CV) or R47H AD risk variant (T2R47H) on a mouse TREM2 KO background 8 to generate APPPS1-21/T2CV (n = 7; 1 female, 6 male) and APPPS1-21/T2R47H (n = 7; 6 female, 1 male) mice. No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in He et al. 14 , which is the only other manuscript to date that has used this experimental strategy. One mouse was excluded from the T2WT group owing to a failed injection, which was apparent upon immunohistochemistry analysis, and this mouse also tested as an outlier by Grubb's test. All mice were bred on a C57BL6 background and housed in pathogen-free conditions under a normal 12-h light/dark cycle. All animal protocols were approved by the Animals Studies Committee at the Washington University School of Medicine in St. Louis.
Preparation of tau aggregates from human Alzheimer's disease brain tissue for injection into mice and biochemical analysis. AD-tau was isolated from a human AD brain, Braak stage V-VI, as described previously 16 . Total protein concentration of the final supernatant was 6.7 µg µl −1 as determined by BCA assay (Thermo Fisher). Protein-specific sandwich enzyme linked immunosorbent assays (ELISAs) were used to determine the amount of tau, amyloid-β 40 , amyloid-β 42 , and alphasynuclein in the AD-tau preparation, the concentrations of which were found to be 1. , respectively. AD-tau was diluted to a final concentration of 0.4 µg µl −1 and stored at −80 °C. Samples underwent one freeze-thaw to be aliquoted for injections. Prior to injection, each aliquot of AD-tau was thawed on ice and sonicated in a water bath sonicator (QSonica, Q700) for 30 s at 65% amplitude at 4 °C.
Stereotactic intracerebral injections.
Mice were anesthetized with isofluorane, immobilized in a stereotactic frame (David Kopf Instruments), and ascetically injected with 2.5 µl of AD-tau in the dentate gyrus (bregma, −2.5 mm; lateral, −2.0 mm; depth, −2.2 mm) and overlying cortex (bregma, −2.5 mm; lateral, −2.0 mm; depth, −1.0 mm) using a syringe (Hamilton; syringe 80265-1702RNR and needle 7803-07). To examine both seeding and spread of tau pathology, mice were unilaterally injected with a total of 2 µg AD-tau (1 µg at each injection site). Mice were allowed to recover on a 37 °C heating pad and monitored for the first 48 h post surgery. All animals underwent the same procedures, therefore no randomization was necessary.
Brain extraction and preparation. Mice were anesthetized with intraperitoneal pentobarbital (200 mg kg −1 ), perfused with 3 U ml −1 heparin in cold Dulbecco's PBS and the brains were extracted carefully. Whole brains were fixed in 4% paraformaldehyde for 2 d before being transferred to 30% sucrose and stored at 4 °C until they were sectioned. Brains were cut coronally into 30 μm sections on a freezing sliding microtome (Leica SM1020R) and stored in cryoprotectant solution (0.2 M phosphate buffered saline, 15% sucrose, 33% ethylene glycol) at −20 °C until use. A small nick was placed with a razor blade on the left hemisphere at the piriform cortex to ensure proper identification of the ipsilateral injected side in subsequent immunostaining experiments.
Immunohistochemistry and immunofluorescence. Immunohistochemistry for NP tau was performed with biotinylated AT8 (AT8b) (Thermo Fisher, MN1020B) at a 1:500 dilution. A biotinylated in-house human tau 25-30 specific antibody 23 was used to detect injected human AD-tau at a 1:500 dilution. For immunohistochemistry, sections were washed 3 times for 5 min in Tris-buffered saline (TBS), then placed in 0.3% hydrogen peroxide for 10 min. After washing, sections were blocked in 3% milk 0.25% TBS-triton-X-100 (TBS-X) for 30 min and then placed in primary antibody overnight at 4 °C. The next day, sections were washed and placed in ABC Elite (Vector Laboratories, PK-4000) for 1 h washed again, and developed in DAB (Sigma Aldrich, D4293) supplemented with 0.225% hydrogen peroxide and 0.1% nickel chloride. Sections were mounted, allowed to dry overnight, dehydrated in sequential alcohol dilutions followed by xylene and then sealed with Cytoseal (Thermo Fisher, 8310). Immunofluorescence co-stains were performed for (1) X34, amyloid-β 42 , AT8, and Iba1, or (2) X34, AT8, and BACE1. Fibrillar amyloid-β was stained by X34 dye (Sigma, SML-1954) and antibodies to AT8, amyloid-β 42 (Thermo Fisher, 700254, 1:500), Iba1 (Abcam, ab5076, 1:2000), and BACE1 (Abcam, ab108394, 1:500) were used to interrogate peri-plaque pathologies. All stains were performed with free-floating sections on a shaker at room temperature (~20 °C) unless otherwise indicated. For immunofluorescence, sections were washed and then permeabilized in 0.25% triton-X-100 phosphate-buffered saline (PBS-X) for 30 min. Lipofuscin was quenched with 0.1% Sudan black, washed once in 0.02% PBS-tween-20 and again in PBS. Tissue was then incubated in X34 for 20 min, washed 3 times in X34 buffer (40% EtOH in PBS), and washed in PBS 2 times. Sections were then blocked for 30 min in 3% bovine serum albumin, 3% normal goat serum, 0.1% PBS-X for 30 min, before being placed in primary antibodies diluted in blocking buffer overnight at 4 °C. The next day, sections were washed, placed in secondary antibodies for 2 h (Thermo Fisher, 1:500), and then washed again 3 times for 20 min. Sections were mounted, sealed in ProLong Gold anti-fade (Thermo Fisher, P36930), and stored in the dark at 4 °C until imaging. Additional details on antibodies and reagents can be found in the Life Sciences Reporting Summary accompanying this manuscript.
Immunofluorescence of human tissue. Slides with 8 μm thick sections of prefrontal cortex from TREM2 CV and R47H or R62H AD cases were costained for X34, amyloid-β 42 and AT8 using the immunofluorescence protocol described previously, with the addition of a 10 min antigen retrieval step in boiling citrate buffer prior to permeabilization in PBS-X. Cases were obtained from the Alzheimer's Disease Research Center at Washington University St. Louis. All TREM2 R47H and TREM2 R62H cases were paired with a TREM2 CV case control that was matched by age, gender, and apolipoprotein E status (Supplementary Table 1) .
Image acquisition and analysis. Stains were quantified from 3-4 sections per a subject for immunohistochemistry and 2-3 sections for immunofluorescence. In immunofluorescence images, on average there were 1-4 plaques for mouse stains and 3-6 plaques for human stains within a given image. Notably, the number of plaques and plaque size was not significantly different between compared groups for all confocal analyses. For immunohistochemistry stains, slides were scanned using a NanoZoomer digital pathology system (Hamamatsu Photonics, Middlesex, NJ) and images were processed using NDP viewing software (Hamamatsu) and ImageJ software version 2.0.0 (US National Institutes of Health). For immunofluorescence, 2 or 3 z-stacks per section were acquired on an LSM 880 II Airyscan FAST confocal microscope (Zeiss) with a 20× objective. Quantification of confocal images for p-tau and amyloid-β 42 around X34
+ plaques was performed on a semi-automated platform using MATLAB and Imaris 9.2 software (Bitplane) to create surfaces of each stain based on a threshold applied to all images, dilate X34 surfaces 15 µm, and co-localize various immuno-stained surfaces and dilated X34 surfaces. For quantification of the number of plaque-associated microglia, a threshold was applied across all images to assign spots to each microglial cell body. X34 surfaces were dilated 15 µm, and spots were manually counted within the X34 + extended surface. Any spots fully within or partially touching the extended surface were included in the analysis. AT8 stained NFTs were manually counted in the ipsilateral cortex and hippocampus of seeded mice. All staining experiments were imaged and quantified by a blinded observer. Representative images were further processed using ImageJ Fiji, Illustrator and Photoshop CC 2017 (Adobe Systems). R studio (v. 1.1.456) was used to generate plots comparing different AT8, amyloid-β 42 , and microglia cells surrounding X34 + plaques.
Tau ELISAs. The concentration of total soluble and insoluble tau from human AD cases (Supplementary Table 2 ) was quantified in a tau sandwich ELISA as described previously 19 using Tau-5 as the coating antibody and human-specific biotinylated HT7 for detection. For quantification of total soluble and insoluble p-tau, 96-well half-area plates were coated with 20 μg ml −1 of an in-house p-S181-tau antibody and incubated at 4 °C overnight. The next day, the plate was blocked in 3% BSA (RPI) in PBS for 1 h at 37 °C. Next, tau-178-225 (pS181, pS198, pS199, pS202, pT205) standard peptides and samples were diluted in sample buffer (0.25% BSA-PBS, 1× protease inhibitor, 3,300 mM Tris pH 8.0, PBS), loaded onto the plate, and incubated at 4 °C overnight. On the third day, 0.3 μg ml −1 of biotinylated AT8 (pS202/pT205) (Thermo Fisher) was applied to the plate for 1.5 h at 37 °C, then Streptavidin-poly-HRP-40 (1:10,000) (Fitzgerald) was applied for 1.5 h at room temperature. TMB Superslow Substrate solution (Sigma) was added and the plates were read at 650 nm on a Biotek plate reader after developing for 30 min at room temperature. All samples were run in triplicate and results are reported from the first freeze-thaw and testing of the samples. Sample were run and quantified by a blinded observer.
Statistics. GraphPad Prism 5.01 was used to perform statistical analyses. All graphs represent the mean of all samples in each group ± s.e.m. Sample sizes are reported within each figure and are reflective of individual subjects. All data were normally distributed and equal variances were formally tested. Significance was determined by unpaired Student's t-test unless otherwise stated in figure legends and P < 0.05 was considered significant. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding authors upon reasonable request.
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
